Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 968 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Endocrine therapy Clear all
Recruiting Phase 2 Interventional

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer

NCT06361940
View directory record Official record
Conditions
Breast Cancer
Interventions
Aromatase inhibitors or tamoxifen
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 4, 2026, 2:38 AM EDT
Active, not recruiting Phase 2 Interventional

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004
View directory record Official record
Conditions
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
(Z)-endoxifen, goserelin
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Not yet recruiting Not applicable Interventional

CGM After Discharge From Hospital

NCT07510386
View directory record Official record
Conditions
Type 2 Diabetes, Steroid-induced Diabetes
Interventions
Libre 3 Plus continuous glucose monitoring (CGM) system, Blinded Continuous Glucose Monitoring, Finger stick
Device · Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Completed Not applicable Interventional

Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer

NCT02400060
View directory record Official record
Conditions
Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage 0 Breast Cancer
Interventions
Telephone-Based Intervention, Survey Administration, Laboratory Biomarker Analysis
Behavioral · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Goldsboro, North Carolina • Winston-Salem, North Carolina • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 4, 2026, 2:38 AM EDT
Active, not recruiting Phase 1 Interventional

Selumetinib and Olaparib in Solid Tumors

NCT03162627
View directory record Official record
Conditions
Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands
Interventions
Selumetinib, Olaparib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

NCT02115282
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
652
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Islet Transplantation in Type 1 Diabetic Patients Using the Edmonton Protocol of Steroid Free Immunosuppression

NCT00566813
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Islet Cell Transplant, Islet Cell Transplant plus
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Sep 4, 2026, 2:38 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men

NCT04922424
View directory record Official record
Conditions
Hypertension, Hyperlipidemias
Interventions
Atorvastatin, placebo
Drug · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 35 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Sep 4, 2026, 2:38 AM EDT
Terminated Phase 4 Interventional Results available

Pharmacokinetics and Pharmacogenomics of Ribociclib in Race-based Cohorts

NCT04657679
View directory record Official record
Conditions
Breast Cancer
Interventions
Ribociclib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 4, 2026, 2:38 AM EDT
Completed Not applicable Interventional

Randomized Study of Sequential Orbital Radiotherapy for Graves' Ophthalmopathy

NCT00004660
View directory record Official record
Conditions
Graves' Disease
Interventions
Radiotherapy, Sham treatment
Radiation
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
30 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 1998
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 4, 2026, 2:38 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Efficacy of Acupuncture for Hot Flashes in Women Treated With Hormonal Therapy for Breast Cancer

NCT00209001
View directory record Official record
Conditions
Breast Cancer
Interventions
Acupuncture, Sham acupuncture therapy
Procedure
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 12, 2015 · Synced Sep 4, 2026, 2:38 AM EDT
Completed Phase 4 Interventional

Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance

NCT05058209
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Drug
Lead sponsor
ROC Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 4, 2026, 2:38 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes

NCT00891995
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Closed loop, Home glucose monitoring, Insulin pump, Continuous glucose monitor
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Sep 4, 2026, 2:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

NCT05768139
View directory record Official record
Conditions
Breast Cancer, Solid Tumors, Adult
Interventions
STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
28
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Not listed No phase listed Observational

Quality of Life Study for Prostate Cancer Patients

NCT00561444
View directory record Official record
Conditions
Prostate Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
1,051 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
3
States / cities
Voorhees Township, New Jersey • Albuquerque, New Mexico • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Sep 4, 2026, 2:38 AM EDT
Recruiting Not applicable Interventional

Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)

NCT07454499
View directory record Official record
Conditions
Cancer
Interventions
Digital Endocrine therapy Symptom Monitoring and Education Intervention
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Clascoterone for Steroid-related Acne Vulgaris in Transgender Male Patients Receiving Masculinizing Hormone Therapy

NCT05891795
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clascoterone 1% Top Cream, Vehicle
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Terminated Phase 1 Interventional Results available

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

NCT01296555
View directory record Official record
Conditions
Solid Cancers, Non-Hodgkin's Lymphoma
Interventions
Fulvestrant, GDC-0032, Letrozole, Midazolam
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
27
States / cities
Scottsdale, Arizona • Tucson, Arizona • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Sep 4, 2026, 2:38 AM EDT
Terminated Phase 2 Interventional Results available

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

NCT00611715
View directory record Official record
Conditions
Breast Cancer
Interventions
erlotinib hydrochloride, letrozole, fluorescence in situ hybridization, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Macon, Georgia • Hopkinsville, Kentucky • Paducah, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Sep 4, 2026, 2:38 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

NCT03361735
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy, Radium Ra 223 Dichloride, Laboratory Biomarker Analysis, Degarelix
Drug · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Completed Phase 3 Interventional

The Effect of Growth Hormone in Very Young Girls With Turner Syndrome

NCT00406926
View directory record Official record
Conditions
Turner Syndrome
Interventions
Somatropin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
9 Months to 4 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2003
U.S. locations
10
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2006 · Synced Sep 4, 2026, 2:38 AM EDT
Active, not recruiting Phase 1 Interventional

To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer

NCT03006172
View directory record Official record
Conditions
Breast Cancer, Solid Tumor
Interventions
Inavolisib, Fulvestrant, Letrozole, Palbociclib, Metformin, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Boston, Massachusetts • New York, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Completed Phase 3 Interventional Results available

Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

NCT00601900
View directory record Official record
Conditions
Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v6, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Bevacizumab, Laboratory Biomarker Analysis, Letrozole, Questionnaire Administration, Tamoxifen Citrate
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
521
States / cities
Mobile, Alabama • Fort Smith, Arkansas • Antioch, California + 355 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 4, 2026, 2:38 AM EDT
Recruiting Phase 1 Interventional

Reversing InGuinal Hernia Trial: The Evaluation of Sex Hormones to Reverse Inguinal Hernias in Males

NCT07604272
View directory record Official record
Conditions
Inguinal Hernia Unilateral, Inguinal Hernia Bilateral, Inguinal Hernia Without Obstruction or Gangrene, Inguinal Hernia, Without Mention of Obstruction or Gangrene
Interventions
Fulvestrant, Anastrozole (ARIMIDEX™)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 4, 2026, 2:38 AM EDT